| Literature DB >> 30115340 |
Jason Lohr1, Norman Benjamin Fredrick2, Leesha Helm3, Jeffrey Cho4.
Abstract
Most travel medical care is provided by patients' primary care physicians; only 10% of international travelers visit a travel clinic. The main purposes for travel include vacationing, visiting friends and family, business, and for educational purposes. The purposes of the pretravel consultation are to estimate risk and provide recommendations to mitigate risk.Entities:
Keywords: Posttravel Assessment; Pretravel Assessment; Travel abroad; Travel health
Mesh:
Year: 2018 PMID: 30115340 PMCID: PMC7119335 DOI: 10.1016/j.pop.2018.05.012
Source DB: PubMed Journal: Prim Care ISSN: 0095-4543 Impact factor: 2.907
Health kit item checklist
| Prescription Medications | Over-the-Counter Medications | Injury/Illness Prevention |
|---|---|---|
| Regular medications | Tylenol | Insect repellant for skin and clothing |
Abbreviation: HIV, human immunodeficiency virus.
If indicated.
Travel vaccines, including routine vaccines of high priority in travelers
| Vaccine | Indication | Administration |
|---|---|---|
| Hepatitis A | All travelers ≥1 y of age | 2 doses |
| Hepatitis B | All travelers | 3 doses Administer ≥6 mo before travel |
| Influenza | All travelers ≥6 mo of age | 1 dose Booster: annual |
| Tetanus, diphtheria, pertussis (Td, Tdap) | All travelers | Td every 5 y for adult travelers Tdap: Adolescents age 11–18 y, or age ≥19 if no Tdap administered prior Pregnancy between 27 and 36 wk gestation |
| Cholera | Age 18–64 Individuals at high risk (health care workers) | 1 dose Booster: undetermined |
| Japanese encephalitis | Travelers to high-risk areas (Asia, Western Pacific) >1 mo travel Travel to rural areas | 2 doses on days 0 and 28 Booster: 1 y |
| Meningococcal meningitis | Travelers to specific areas of Africa associated with meningitis Travelers to crowded spaces (dormitories) | Age 2–55, 1 dose MenACWY Age ≥56 who have never received the vaccine, 1 dose MPSV4 Booster: 5 y after last dose if individual received dose at age ≥7 |
| Polio | Travelers to countries with increased prevalence of polio (eg, Pakistan, Afghanistan, Nigeria) | 4 dose childhood series (2, 4, 6–18 mo, and 4–6 y of age) Plus Single dose inactivated virus for all adults Booster: not indicated Administer 4 wk to 12 mo before travel |
| Rabies | Travelers to remote, rural areas Long-term travelers Wildlife workers, spelunkers | 3 doses on days 0, 7, 21 or 28 Booster: If at high risk, check serology every 2 y, and administer booster if low antibodies If low risk: No booster indicated |
| Typhoid fever | All travelers to low-income nations, rural travel, or high-risk areas Duration of travel >1 mo | Oral: 1 tab taken every other day for 7 d for 5-y protection IM: 1 dose for 2 y of protection Booster: repeat oral or IM at appropriate interval |
| Yellow fever | Travelers to tropical Africa and South America Not indicated for travelers <9 mo of age | Single dose Contraindicated in immunosuppressed individuals Increased risk of adverse events for first time recipients age >60 y |
Abbreviations: IM, intramuscularly; MPSV4, meningococcal polysaccharide vaccine.
Treatment of traveler’s diarrhea based on severity
| Mild: tolerable diarrhea, does not interfere for activity, often resolves within 2–5 d | Moderate: distressing diarrhea, interferes with activity | Severe: incapacitating diarrhea, prevent activity |
| Loperamide or bismuth subsalicylate; hydration | Hydration Antibiotics may be used including Fluoroquinolones Azithromycin Rifaximin Loperamide can be used in conjunction with antibiotics or as a monotherapy. | Emergency care Antibiotics should be used including Azithromycin (preferred) Fluoroquinolones or rifaximin (can be used for nondysenteric, severe traveler’s diarrhea). |
Top infectious causes of persistent traveler’s diarrhea listed in decreasing order of frequency in each column
| Protozoa | Bacteria |
|---|---|
|
|
Top febrile illnesses to consider in returned travelers based on location
| Febrile Illness | Location |
|---|---|
| Malaria (21%) | Sub-Saharan Africa, Oceania (especially Papua New Guinea) |
| Dengue fever (6%) | Southeast Asia, Central and South America, Caribbean |
| Enteric fever (2%) | South Central Asia (ie, Indian subcontinent) |
| Rickettsioses (2%) | Southern Africa (especially African tick bite fever in South Africa) |
Common medications for altitude illness
| Drug | Indication | Dose |
|---|---|---|
| Acetazolamide | AMS, HACE prevention | 125 mg PO BID starting 12 h prior |
| AMS treatment | 250 mg PO BID | |
| Dexamethasone | AMS, HACE prevention | 4 mg PO every 12 h |
| AMS, HACE treatment | 8 mg PO once, then 4 mg PO every 6 h | |
| Nifedipine | HAPE prevention/treatment | 30 mg SR PO every 12 h |
Abbreviations: AMS, acute mountain sickness; BID, twice per day; HACE, high altitude cerebral edema; HAPE, high altitude pulmonary edema; PO, by mouth.
Common preventive medications for motion sickness
| Drug | Dose | Side Effects |
|---|---|---|
| Dimenhydrinate (Dramamine) | 50 mg PO every 4–6 h | Sedation |
| Meclizine (Antivert) | 25–50mg 1 hour before travel, every 24 h | Mild sedation |
| Scopolamine patch (Transderm Scop) | 1 patch applied every 72 h | Dry mouth, blurry vision |
Abbreviation: PO, by mouth.
| Air | Sit at window seat over wing and look out window |
| Motor vehicle | Sit in front seat, semireclining position, avoid head motion, view horizon |
| Sea | Chose cabin in middle of ship near the waterline |